title: Optimal markers for real-time quantitative reverse transcription PCR detection of circulating tumor cells from melanoma, breast, colon, esophageal, head and neck, and lung cancers.
abstract: BACKGROUND
  The detection of circulating tumor cells (CTCs) may prove useful for screening, prognostication, and monitoring of response to therapy. However, given the large background of circulating cells, it is probably necessary to detect 1 cancer cell in >10(6) leukocytes. Although reverse transcription (RT)-PCR is potentially sensitive and specific enough to achieve this goal, success will require the use of appropriate mRNA markers. The goal of this study was to identify optimal marker combinations for detection of CTCs.
  
  
  METHODS
  An extensive literature and internet database survey was conducted to identify potential markers. We then used real-time quantitative RT-PCR to test for expression of selected potential markers in tissue samples from primary tumors of breast, colon, esophagus, head and neck, lung, and melanoma and normal blood samples. Markers with high expression in tumors and a median 1000-fold lower expression in normal blood were considered potentially useful for CTC detection and were tested further in an expanded sample set.
  
  
  RESULTS
  A total of 52 potential markers were screened, and 3-8 potentially useful markers were identified for each tumor type. The mRNAs for all but 2 markers were found in normal blood. Marker combinations were identified for each tumor type that had a minimum 1000-fold higher expression in tumors than in normal blood.
  
  
  CONCLUSIONS
  Several mRNA markers may be useful for RT-PCR-based detection of CTCs from each of 6 cancer types. Quantification of these mRNAs is essential to distinguish normal expression in blood from that due to the presence of CTCs. Few markers provide adequate sensitivity individually, but combinations of markers may produce good sensitivity for detection of the presence of these 6 neoplasms.
authors.affiliation: Mount Sinai School of Medicine, New York, NY 10029, USA.
authors.forename: Liqiang
authors.initials: L
authors.lastname: Xi
authors.forename: Daniel G
authors.initials: DG
authors.lastname: Nicastri
authors.forename: Talal
authors.initials: T
authors.lastname: El-Hefnawy
authors.forename: Steven J
authors.initials: SJ
authors.lastname: Hughes
authors.forename: James D
authors.initials: JD
authors.lastname: Luketich
authors.forename: Tony E
authors.initials: TE
authors.lastname: Godfrey
mesh_terms: D014408:Biomarkers, Tumor / Q000096:biosynthesis* / Q000097:blood / Q000235:genetics; D001943:Breast Neoplasms / Q000175:diagnosis / Q000378:metabolism; D003110:Colonic Neoplasms / Q000175:diagnosis / Q000378:metabolism; D004938:Esophageal Neoplasms / Q000175:diagnosis / Q000378:metabolism; D006258:Head and Neck Neoplasms / Q000175:diagnosis / Q000378:metabolism; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis / Q000378:metabolism; D008545:Melanoma / Q000175:diagnosis / Q000378:metabolism; D009369:Neoplasms / Q000175:diagnosis* / Q000378:metabolism; D009360:Neoplastic Cells, Circulating / Q000378:metabolism*; D012333:RNA, Messenger / Q000096:biosynthesis / Q000097:blood; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012680:Sensitivity and Specificity
chemical_list: D014408:Biomarkers, Tumor; D012333:RNA, Messenger